Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -215.82% | -370.07% | -444.98% | 127.30% | 203.32% |
| Total Depreciation and Amortization | -34.10% | -22.33% | -1.53% | 34.38% | 79.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 141.24% | 206.79% | 154.47% | -602.52% | -636.33% |
| Change in Net Operating Assets | -187.92% | 189.86% | 218.69% | 172.00% | 192.12% |
| Cash from Operations | -962.57% | -68.03% | 18.29% | 53.25% | 91.82% |
| Capital Expenditure | 37.84% | 66.67% | 92.91% | 98.21% | 94.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -162.90% | 433.96% | 245.41% | 231.96% | 637.60% |
| Cash from Investing | -162.96% | 433.26% | 244.88% | 231.18% | 615.61% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 100.00% | 55.72% | 0.90% | -198.20% | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | -142,750.00% | -124,200.00% | -124,200.00% | -64,450.00% | 98.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -142,750.00% | -208.14% | -200.11% | -193.45% | -100.02% |
| Foreign Exchange rate Adjustments | 242.86% | 76.47% | 92.59% | 103.59% | 78.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.42% | 1,111.94% | 244.43% | 232.13% | 437.24% |